Clinical trials: Severe Respiratory Distress
Multiple Trauma, Respiratory Distress Syndrome, Adult
Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma
Severe hypoxemia following trauma may happen in many circumstances (aspiration, ventilation-associated pneumonia, lung contusion...), most of which are not exclusively associated with a direct injury to the lungs.
- Trial name
- TRAUMADORNASE (NCT03368092)
- Testing
- Dornase Alfa Inhalant Solution [Pulmozyme]
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Acute Respiratory Distress Syndrome, Adult
Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells
This is a multi-center, open-label, non-randomized controlled trial. Patients with viral-induced acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO) will be eligible.
- Trial name
- NCT02215811
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Karolinska University Hospital
Covid19, Hypoxemia
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
Patients with COVID-19 frequently develop lower respiratory complications. Difficulty breathing and a low concentration of oxygen in the blood are of concern in patients with COVID-19, as they indicate that the lungs may be…
- Trial name
- NCT04771000
- Testing
- Ambrisentan
- Where
- 13 sites in Croatia, Spain
- Volunteers
- 88 people
- Sponsor
- Noorik Biopharmaceuticals AG
Respiratory Distress Syndrome
Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide
Exogenous bolus surfactant administration may affect hemodynamic parameters and peripheral perfusion. Surfactant therapy is commonly used for respiratory distress syndrome in premature infants, which is also associated with…
- Trial name
- NCT01923844
- Testing
- exogenous surfactant
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Ege University
Acute Respiratory Distress Syndrome (ARDS), Intensive Care Units (ICUs)
Assessment of the PEEP Responsiveness to Titrate End-expiratory Pressure and of the Need for Muscle Relaxation During Prone Positioning in Moderate-to-severe Acute Respiratory Distress Syndrome: A Master Protocol
Despite best supportive care, mortality of the Acute Respiratory Distress Syndrom (ARDS) remains high. In the absence of specific treatments, providing safe and efficient mechanical ventilation (MV) is key to survival.
- Trial name
- PEPER (NCT06849570)
- Testing
- Minimal distension, Maximal Recruitment, Prone position + early NMBAs
- Where
- 29 sites in France
- Volunteers
- 1,200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Infant, Newborn, Hypertension, Pulmonary
Early Inhaled Nitric Oxide for Respiratory Failure in Newborns
This prospective, randomized controlled trial tested whether initiating iNO therapy earlier would reduce death and reduce the use of extracorporeal membrane oxygenation (ECMO) -- temporary lung bypass -- therapy compared with the…
- Conditions
- Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration
- Trial name
- Early iNO (NCT00005773)
- Testing
- Inhaled Nitric Oxide, Standard iNO therapy
- Where
- 18 sites in United States
- Volunteers
- 302 people
- Sponsor
- NICHD Neonatal Research Network
Respiratory Distress Syndrome, Adult
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have acute respiratory distress syndrome (ARDS).
- Trial name
- INTEREST (NCT02622724)
- Testing
- Interferon beta-1a
- Where
- 71 sites in Belgium, Czechia and 6 more
- Volunteers
- 301 people
- Sponsor
- Faron Pharmaceuticals Ltd
Infant, Newborn, Infant, Low Birth Weight
Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure
This multicenter trial tested whether inhaled nitric oxide would reduce death or the need for oxygen in preterm infants (less than 34 weeks gestational age) with severe lung disease.
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Trial name
- Preemie iNO (NCT00016523)
- Testing
- Inhaled nitric oxide
- Where
- 17 sites in United States
- Volunteers
- 420 people
- Sponsor
- NICHD Neonatal Research Network
COVID-19
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF) versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure.
- Trial name
- SARPAC (NCT04326920)
- Testing
- Sargramostim, Control
- Where
- 4 sites in Belgium
- Volunteers
- 87 people
- Sponsor
- University Hospital, Ghent
Respiratory Distress Syndrome, Acute, Severe Community-Acquired Pneumonia
Multimodal Database and Large Language Model for ARDS
The goal of this observational study is to integrate existing clinical cohorts from the research team to establish dedicated cohorts for ARDS and high-risk ARDS patients (primarily SCAP patients), then systematically collect…
- Trial name
- NCT06973733
- Testing
- Clinical data and biospecimen collection
- Volunteers
- 6,500 people
- Sponsor
- China-Japan Friendship Hospital
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
COVID-19, SARS-CoV Infection
Glycine Supplement for Severe COVID-19
This study will explore whether a daily supplement of glycine, a substance that has antiinflammatory, cytoprotective, and endothelium-protecting effects, can improve mortality, as well as clinical and biochemical parameters, in…
- Conditions
- COVID-19, SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia
- Trial name
- NCT04443673
- Testing
- Glycine
- Where
- Mexico
- Volunteers
- 59 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
Multiple Osteochondroma, Osteogenesis Imperfecta
Resilience and Coping in a Rare Skeletal Disease Population to Face Coronavirus (COVID-19) Outbreak Distress: a Longitudinal Study
In the COVID-19 outbreak context, people living with rare diseases have been highly troubled with anxiety, loneliness, and depression.
- Conditions
- Multiple Osteochondroma, Osteogenesis Imperfecta, Ollier Disease, Maffucci Syndrome
- Trial name
- RELOAD (NCT04844697)
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Istituto Ortopedico Rizzoli
COVID-19, Acute Respiratory Distress Syndrome
Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS
A phase1/2, open label, dose escalation, safety and early efficacy study of CAStem for the treatment of severe COVID-19 associated with or without ARDS.
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Virus; Pneumonia, Acute Lung Injury
- Trial name
- NCT04331613
- Testing
- CAStem
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese Academy of Sciences
Severe Acute Respiratory Syndrome
Effect of Early Implementation of Prone Positioning
Background and objective: The ramifications of early lung protective measures and prone positioning on the ICU length of stay rates of participants admitted to the ICU with acute respiratory distress syndrome amid the COVID-19…
- Trial name
- prone (NCT06287554)
- Testing
- PRONE POSITION
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Zulekha Hospitals
ARDS, Human, Extracorporeal Membrane Oxygenation Complication
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
Acute respiratory distress syndrome (ARDS) is a lesional pulmonary edema that occurs as a result of direct or indirect lung injury.
- Conditions
- ARDS, Human, Extracorporeal Membrane Oxygenation Complication, Hypothermia
- Trial name
- HypoLungECMO (NCT05306392)
- Testing
- Moderate Hypothermia, Normothermia
- Volunteers
- 30 people
- Sponsor
- Central Hospital, Nancy, France
Influenza, Severe Acute Respiratory Distress Syndrome
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
This study will examine the safety of an experimental medication called Poly-ICLC, developed for preventing or reducing the severity of infections from influenza and other viruses acquired through the nose, mouth and lungs.
- Conditions
- Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola
- Trial name
- NCT00646152
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Pneumonia
Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19)
Acute respiratory distress syndrome (ARDS) is a syndromic definition of an acute lung injury with alteration of biomechanics (lower respiratory system compliance) mostly associated with increased lesional edema.
- Conditions
- COVID-19, Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- PiCCOVID (NCT04376905)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Montpellier
Severe Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS)
Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure
This is a phase I/II, randomized, double-blind, placebo-controlled clinical trial that will evaluate the safety and potential efficacy of therapy with extracellular vesicles (EVs) obtained from mesenchymal stromal cells (MSCs)…
- Conditions
- Severe Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS), Pneumonia
- Trial name
- NCT06002841
- Testing
- intravenous treatment with EVs
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- D'Or Institute for Research and Education